Kymera Therapeutics Q4 EPS $(0.97) Misses $(0.78) Estimate, Sales $2.871M Miss $14.798M Estimate. Cash And Equivalents Of $1.6B
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.78) by 24.36 percent. This is a 10.23 percent decrease over losses of $(0.88) per share
